Questcor Pharmaceuticals — JMP Securities Healthcare Conference 2012
21 slides from Questcor Pharmaceuticals's conference presentation, Jul 13, 2012
Slide 1: JMP Securities Healthcare Conference
NASDAQ: QCOR July 13, 2012 JMP Securities Healthcare Conference Exhibit 99.1 1 NASDAQ: NASDAQ: QCOR QCOR July 13, 2012 July 13, 2012 JMP Securities Healthcare Conference JMP Securities Healthcare Conference
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 3: Questcor Overview
Flagship Product: • Profitable, cash flow positive, $115M** in cash, debt-free • 19 approved indications Key Markets*: • Nephrotic Syndrome, Multiple Sclerosis, Infantile Spasms • Several billion dollar market opportunity Strategy: • Grow Acthar sales in each key market • Developing Rheumatology and
Slide 4: Q2 2012 Rx Metrics
• Paid Rxs (estimated) • Shipped 4,710 vials in Q2-2012 – Compares to 4,111 vials in Q1-12 and 2,430 in Q2-11 – Channel inventory level in the normal range on 6/30/2012 Q2 2012 Rx Metrics Notes: Paid Rx information based on internal estimates. The table includes "Related Conditions" - diagnoses that
Slide 5: Strategic Plan - Focus on the Embedded Pipeline in Acthar
5 • Expand Nephrotic Syndrome promotion effort • Expand Multiple Sclerosis promotion effort • Maintain Infantile Spasm promotion effort • Initiate pilot Rheumatology promotion activity • Develop other markets for Acthar Strategic Plan- Focus on the Embedded Pipeline in Acthar • Expand Nephrotic Synd
Slide 6: David Young, Pharm.D., Ph.D. Chief Scientific Officer
David Young, Pharm.D., Ph.D. Chief Scientific Officer 6 David Young, Pharm.D., Ph.D. David Young, Pharm.D., Ph.D. Chief Scientific Officer Chief Scientific Officer
Slide 7: Making A Significant Investment in Research
Making A Significant Investment in Research 7 Breakouts exclude chemistry & manufacturing expense; *Estimated
Slide 8: Understanding Acthar: clinical use
8 • Clinical use of Acthar – Nonclinical research – Clinical research • On-label indications – Proteinuria in nephrotic syndrome (NS), multiple sclerosis (MS) flares, infantile spasms, lupus • Off-label indications – Diabetic nephropathy, traumatic brain injury, autism, MS maintenance treatment Acad
Slide 9: Understanding Acthar: science of how it works and clinical use
9 • Understanding the biological properties of Acthar – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory • On-label indications – Proteinuria in NS, MS flares, Lupus • New indications – Nephrology (eg, diabetic nephropathy) – Indications with autoimmune/infl
Slide 10: Some Questions We Have Been Addressing
10 • WHY will Acthar be difficult to copy? • WHY is Acthar different than steroids? • WHY does Acthar work in multiple indications? • HOW can Acthar's use be expanded? Some Questions We Have Been Addressing • WHY will Acthar be difficult to copy? • WHY is Acthar different than steroids? • WHY does A
Slide 11: Acthar History
11 Acthar History 1950 200 0 0 2010 1968-1973 DESI review = steroid label > 50 indications 1950 indication added 2000 2001-2003 Questcor acquires Acthar Gel (MR), FDA approves manufacturing 2010 Infantile spasms approved, Label modernized steroid & 19 indications 2009-Present Expanding Acthar Gel (M
Slide 12: Chemistry Overview Of Acthar Gel
12 • Porcine ACTH differs from humans by 1 amino acid • Acthar is extracted from the pituitary of pigs • Peptide composition is being investigated - multiple peptides exist in Acthar Chemistry Overview Of Acthar Gel • Porcine ACTH differs from humans by 1 amino acid • Acthar is extracted from the pi
Slide 13: Many Biologically Active Peptides in Pituitary (>100)
13 Many Biologically Active Peptides in Pituitary (>100) How many active peptides are in Acthar?
Slide 14: How Does Acthar Work?
14 • Acthar is complex mixture of active peptides that we are only beginning to identify and understand • Acthar acts like a combination product Multiple Peptides Multiple Pharmacological Properties Multiple Indications Difficult to copy How Does Acthar Work? • Acthar is complex mixture of active pe
Slide 15: Old Paradigm - ACTH and Acthar Biology Defined by Steroidogenic Activity
15 Old Paradigm - ACTH and Acthar Biology Defined by Steroidogenic Activity Adrenal cortex Anterior Pituitary Hypothalamus ACTH Corticotropin Releasing Factor (CRF) Steroidogenesis Indirect regulation of inflammation, immune function and CNS actions via increased glucocorticoids (adrenocorticotropic
Slide 16: Functional Potency at Melanocortin Receptor Subtypes
16 Ligand MC1R MC2R MC3R MC4R MC5R Functional Potency at Melanocortin Receptor (MCR) Subtypes Relative to that of the Endogenous Agonist ACTH(1-39) at MC2R Acthar ++ ++ ++ ++ + Endogenous Agonist, ACTH(1-39) ++ ++ ++ ++ + ACTH(1-24) ++ +++ ++ ++ + -Methylprednisolone Inactive Inactive Inactive Inact
Slide 17: Melanocortin Receptors (MCRs) Distributed Throughout the Body
17 5 Melanocortin Receptors (MCRs) Distributed Throughout the Body Immune Cells CNS Adrenal Gland Kidney Cortisol Cytokines Glial Regulation Decrease Proteinuria
Slide 18: New Paradigm - Acthar Peptides Indirect & Direct Pharmacological Effect
New Paradigm - Acthar Peptides Indirect & Direct Pharmacological Effect 18 Immune Cells CNS Adrenal Gland Glial Regulation Cortisol Cytokines Decrease Proteinuria Kidney
Slide 19: Acthar has Unique Biological and Clinical Properties - Different than Steroids
19 • Receptor binding results • In vitro and in vivo pharmacology studies investigating Acthar's immunomodulation and anti-inflammatory effect • In vivo disease animal models • Clinical evidence Acthar has Unique Biological and Clinical Properties – Different than Steroids • Receptor binding results
Slide 20: Conclusion: Increasing Research Investment
20 • Continuing our research to prevent an equivalent competitive product (company sponsored R&D) • Expanding research to improve market penetration for on-label indications (investigator initiated and company sponsored R&D) • Expanding research to move into new indication markets (company sponsored
Slide 21: JMP Securities Healthcare Conference
NASDAQ: QCOR 21 July 13, 2012 July 13, 2012 JMP Securities Healthcare Conference JMP Securities Healthcare Conference NASDAQ: NASDAQ: QCOR QCOR
Questcor Pharmaceuticals — JMP Securities Healthcare Conference 2012 on 6ix